$ARMP 8-K SEC Filings

Filed On	Filing
23 Sep 2026	8-K: Other Events Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
14 Sep 2026	8-K: Regulation FD Disclosure Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies
12 Aug 2026	8-K: Results of Operations and Financial Condition
20 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
20 Jul 2026	8-K: Regulation FD Disclosure
13 Jul 2026	8-K: Regulation FD Disclosure
23 Jun 2026	8-K: Other Events
16 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
13 May 2026	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
07 May 2026	8-K: Regulation FD Disclosure
27 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
02 Apr 2026	8-K: Other Events
25 Mar 2026	8-K: Results of Operations and Financial Condition
19 Mar 2026	8-K: Regulation FD Disclosure
23 Feb 2026	8-K: Regulation FD Disclosure
26 Jan 2026	8-K: Entry into a Material Definitive Agreement
13 Jan 2026	8-K: Regulation FD Disclosure
01 Dec 2025	8-K: Entry into a Material Definitive Agreement
12 Nov 2025	8-K: Results of Operations and Financial Condition
22 Oct 2025	8-K: Regulation FD Disclosure

Comments